Abstract
The aim of this study was to test the ability of a live attenuated human immunodeficiency virus type 2 (HIV–2) vaccine to protect cynomolgus monkeys against superinfection with a pathogenic simian immunodeficiency virus (SIVsm) This report is an update on our previously reported observation period of nine months. The new data here show that three of four monkeys vaccinated with live HIV–2 were protected against immunosuppression and SIV–induced disease during more than five years of follow–up. The quality of the immunity was permissive for infection, but monkeys that survived showed restricted viral replication in peripheral blood and lymph nodes. This study shows that it is possible to induce protection against a pathogenic heterologous primate lentivirus and to prevent disease in vaccinated monkeys even if infection is not prevented. These findings provide evidence that protection against AIDS can be achieved by immunization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schultz, A.M. & Stott, E.J. Primate models for AIDS vaccines. AIDS 8, (suppl. 1) 203–212 (1994).
Putkonen, P. et al. Clinical features and predictive markers of disease progression in cynomolgus monkeys experimentally infected with simian immunodeficiency virus. AIDS 6, 257–263 (1992).
Hirsch, V.M., Olmstedt, R.A., Murphey-Corb, M., Purcell, R.H. & Johnsson, P.R., An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339, 389–392 (1989).
Putkonen, P. et al. Experimental infection of cynomolgus monkeys (Macaca fas-cicularis) with simian immunodeficiency virus (SIVsm). J. AIDS 2, 359–365 (1989).
Putkonen, P., Böttiger, B., Warstedt, K., Thorstensson, R., Albert, J., Biberfeld, G. Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. J. AIDS 2, 368–373 (1989).
Wigzell, H. Prospects for an HIV vaccine. FASEB J. 5, 2406–2411 (1991).
Ahmad, S. et al. Reduced virus load in rhesus macaques immunized with re-combinant gp160 and challenged with simian immunodeficiency virus. AIDS Res. hum. Retrovir. 10, 195–204 (1994).
Israel, Z.R. et al. Incomplete protection, but suppression of virus burden, elicited by subunit immunodeficiency virus vaccines. J. Virol. 68, 1843–1853 (1994).
Marthas, M.L. et al. Immunization with a live attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J. Virol. 64, 3694–3700 (1990).
Sujipto, S. et al. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol. 64, 2290–2297 (1990).
Hirsch, V. et al. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodefciency virus vaccine. J. infect, dis. 170, 51–59 (1994).
Schafferman, A. et al. Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge. Vaccine 11, 848–852 (1993).
Daniel, M., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938–1941 (1992).
Putkonen, P. et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 4, 783–789 (1990).
Stott, E.J. Anti-cell antibody in macaques. Nature 353, 393 (1991).
Pantaleo, G. et al. Studies in subject with long-term nonprogressive human immunodeficiency virus infection. New Engl. J. Med. 332, 209–216 (1995).
Cao, Y., Qin, L., Zhang, L., Safrit, J. & Ho, D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl. J. Med. 332, 201–208 (1995).
Gao, F. et al. Genetic diversity of human immunodeficiency virus type 2: Evidence for distinct sequence subtypes with differences in virus biology. J. Virol. 68, 7433–7447 (1994).
Baba, T.W. et al. Pathogenicity of live attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820–1825 (1995).
Ada, G.L. The immunological principles of vaccination. Lancet 335, 523–526 (1990).
Böttiger, B. et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF and HIV-2 (SBL-6669 and a new isolate SBL-K135). AIDS Res. hum. Retrovir. 5, 511–519 (1989).
Albert, J. et al. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II and HTLV-IIIB. AIDS Res. hum. Retrovir. 3, 3–10 (1987).
Putkonen, P. et al. Prevention of HIV-2 and SIVsmby passive immunization in cynomolgus monkeys. Nature 352, 436–438 (1991).
Albert, J., Fenyö, E.M. Simple sensitive and specific detection of HIV-1 in clinical specimens by polymerase chain reaction with nested primers. J. clin. Microbiol. 28, 1560–1564 (1990).
Gao, F. et al. Human infection by genetically diverse SIVsm-related HIV-2 in West Africa. Nature 358, 495–499 (1992).
Zhang, Y.J. et al. Stable biological antigenic characteristics of HIV-2SBL.6669 in non-pathogenic infection of macaques. Virology 200, 583–589 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Putkonen, P., Walther, L., Zhang, YJ. et al. Long–term protection against SIV–induced disease in macaques vaccinated with a live attenuated HIV–2 vaccine. Nat Med 1, 914–918 (1995). https://doi.org/10.1038/nm0995-914
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/nm0995-914
This article is cited by
-
HIV-2 as a model to identify a functional HIV cure
AIDS Research and Therapy (2019)
